|
| 1 |
Treatment after failure of frontline therapy of chronic myeloid leukemia in chronic phase including allogeneic hematopoietic stem cell transplantation
Jieun Uhm
Blood Res.2023;58(S1):S109-S113. Published online 2023 April 30
DOI: http://dx.doi.org/10.5045/br.2023.2023054
|
|
| 2 |
Treatment-free remission after discontinuation of imatinib, dasatinib, and nilotinib in patients with chronic myeloid leukemia
Jae Joon Han
Blood Res.2023;58(S1):S58-S65. Published online 2023 April 7
DOI: http://dx.doi.org/10.5045/br.2023.2023035
|
|
| 3 |
EGFR-TKI Combined with Pemetrexed versus EGFR-TKI Monotherapy in Advanced EGFR-Mutated NSCLC: A Prospective, Randomized, Exploratory Study
Weiguang Gu, Hua Zhang, Yiyu Lu, Minjing Li, Shuang Yang, Jianmiao Liang, Zhijian Ye, Zhihua Li, Minhong He, Xiaoliang Shi, Fei Wang, Dong You, Weiquan Gu, Weineng Feng
Cancer Res Treat.2023;55(3):841-850. Published online 2023 February 13
DOI: http://dx.doi.org/10.4143/crt.2022.1438
|
|
| 4 |
Clinical Impact of Drug Adherence of Tyrosine Kinase Inhibitors in Children with Ph-Positive Acute Lymphoblastic Leukemia
Jun-Xia Wang, Miao-Miao Yang, Li-Peng Liu, Hui-Min Zhang, Meng-Chuan Wang, Yu-Wen Chen, Xiao-Ying Zang, Fang Hu
Cancer Res Treat.2023;55(3):1023-1030. Published online 2023 February 6
DOI: http://dx.doi.org/10.4143/crt.2022.1618
|
|
| 5 |
The Role of Brain Radiotherapy before First-Line Afatinib Therapy, Compared to Gefitinib or Erlotinib, in Patients with EGFR-Mutant Non–Small Cell Lung Cancer
Hyun Ae Jung, Sehhoon Park, Se-Hoon Lee, Jin Seok Ahn, Myung-Ju Ahn, Jong-Mu Sun
Cancer Res Treat.2022;55(2):479-487. Published online 2022 December 27
DOI: http://dx.doi.org/10.4143/crt.2022.1344
|
|
| 6 |
Effect of Afatinib for Lung Cancer on Papillary Thyroid Carcinoma
Sang Hwon Cho, Jin Seok Lee, Hyeok Jun Yun, Yong Sang Lee, Hang-Seok Chang
|
|
| 7 |
Safety and efficacy of nilotinib in adult patients with chronic myeloid leukemia: a post-marketing surveillance study in Korea
Seo-Yeon Ahn, Sang Kyun Son, Gyu Hyung Lee, Inho Kim, June-Won Cheong, Won Sik Lee, Byung Soo Kim, Deog-Yeon Jo, Chul Won Jung, Chu Myoung Seong, Jae Hoon Lee, Young Jin Yuh, Min Kyoung Kim, Hun-Mo Ryoo, Moo-Rim Park, Su-Hee Cho, Hoon-Gu Kim, Dae Young Zang, Jinny Park, Hawk Kim, Seryeon Lee, Sung-Hyun Kim, Myung Hee Chang, Ho Sup Lee, Chul Won Choi, Jihyun Kwon, Sung-Nam Lim, Suk-Joong Oh, Inkyung Joo, Dong-Wook Kim
Blood Res.2022;57(2):144-151. Published online 2022 June 30
DOI: http://dx.doi.org/10.5045/br.2022.2021137
|
|
| 8 |
Lung Related Complications in Patients with Advanced Thyroid Cancer during Lenvatinib Therapy: Case Series and Literature Review
Jee Hee Yoon, A Ram Hong, Hee Kyung Kim, Ho-Cheol Kang
|
|
| 9 |
FLT3 mutations in acute myeloid leukemia: a review focusing on clinically applicable drugs
Jae-Sook Ahn, Hyeoung-Joon Kim
Blood Res.2022;57(S1):32-36. Published online 2022 April 30
DOI: http://dx.doi.org/10.5045/br.2022.2022017
|
|
| 10 |
Efficacy and safety of filgotinib as induction and maintenance therapy for Japanese patients with moderately to severely active ulcerative colitis: a post-hoc analysis of the phase 2b/3 SELECTION trial
Toshifumi Hibi, Satoshi Motoya, Tadakazu Hisamatsu, Fumihito Hirai, Kenji Watanabe, Katsuyoshi Matsuoka, Masayuki Saruta, Taku Kobayashi, Brian G Feagan, Chantal Tasset, Robin Besuyen, Chohee Yun, Gerald Crans, Jie Zhang, Akira Kondo, Mamoru Watanabe
Intest Res.2023;21(1):110-125. Published online 2022 March 11
DOI: http://dx.doi.org/10.5217/ir.2021.00143
|
|
| 11 |
Nilotinib-Induced Acute Interstitial Nephritis during the Treatment of Chronic Myeloid Leukemia
Min Jeong Kim
Kosin Med J.2021;36(2):153-160. Published online 2021 December 31
DOI: http://dx.doi.org/10.7180/kmj.2021.36.2.153
|
|
| 12 |
Current Status and Future Perspective of the Treatment for Radioiodine Refractory Differentiated Thyroid Cancer
Young Kee Shong
|
|
| 13 |
A case report of a patient presented with skin ulcer after treatment of lenvatinib
Serin Cha, Dong Woo Kim, Jung Wan Choe, Tae Hyung Kim, Seung Young Kim, Jong Jin Hyun, Sung Woo Jung, Ja Seol Koo, Young Kul Jung, Hyung Joon Yim
J Liver Cancer.2021;21(2):194-198. Published online 2021 September 30
DOI: http://dx.doi.org/10.17998/jlc.2021.09.20
|
|
| 14 |
The Clinical Outcomes of Different First-Line EGFR-TKIs Plus Bevacizumab in Advanced EGFR-Mutant Lung Adenocarcinoma
Yen-Hsiang Huang, Kuo-Hsuan Hsu, Chun-Shih Chin, Jeng-Sen Tseng, Tsung-Ying Yang, Kun-Chieh Chen, Kang-Yi Su, Sung-Liang Yu, Jeremy J.W. Chen, Gee-Chen Chang
Cancer Res Treat.2022;54(2):434-444. Published online 2021 August 2
DOI: http://dx.doi.org/10.4143/crt.2021.671
|
|
| 15 |
Comparison of the Effectiveness and Clinical Outcome of Everolimus Followed by CDK4/6 Inhibitors with the Opposite Treatment Sequence in Hormone Receptor–Positive, HER2-Negative Metastatic Breast Cancer
Hyehyun Jeong, Jae Ho Jeong, Jeong Eun Kim, Jin-Hee Ahn, Kyung Hae Jung, Sung-Bae Kim
Cancer Res Treat.2022;54(2):469-477. Published online 2021 June 23
DOI: http://dx.doi.org/10.4143/crt.2021.205
|
|
| 16 |
Risk of Tuberculosis Development in Patients with Rheumatoid Arthritis Receiving Targeted Therapy: a Prospective Single Center Cohort Study
Yeo-Jin Song, Soo-Kyung Cho, Hyoungyoung Kim, Hye Won Kim, Eunwoo Nam, Sang-Cheol Bae, Dae Hyun Yoo, Yoon-Kyoung Sung
|
|
| 17 |
Real-world management of chronic myeloid leukemia in South Korea: the TARGET survey
Jieun Uhm, Kyoung Ha Kim, Hyewon Lee, Hawk Kim, Slader Cassandra, Inkyung Joo, Chul Won Jung
Blood Res.2021;56(1):31-37. Published online 2021 January 28
DOI: http://dx.doi.org/10.5045/br.2021.2020260
|
|
| 18 |
Advanced Stage Hepatocellular Carcinoma Successfully Treated with Transarterial Radioembolization and Multi-tyrosine Kinase Inhibitor Therapy
Myung Ji Goh, Wonseok Kang, Dong Hyun Sinn, Geum-Youn Gwak, Yong-Han Paik, Moon Seok Choi, Joon Hyeok Lee, Kwang Cheol Koh, Seung Woon Paik
J Liver Cancer.2020;20(2):160-166. Published online 2020 September 30
DOI: http://dx.doi.org/10.17998/jlc.20.2.160
|
|
| 19 |
Vandetanib for the Management of Advanced Medullary Thyroid Cancer: A Real-World Multicenter Experience
Mijin Kim, Jee Hee Yoon, Jonghwa Ahn, Min Ji Jeon, Hee Kyung Kim, Dong Jun Lim, Ho-Cheol Kang, In Joo Kim, Young Kee Shong, Tae Yong Kim, Bo Hyun Kim
Endocrinol Metab.2020;35(3):587-594. Published online 2020 September 22
DOI: http://dx.doi.org/10.3803/EnM.2020.687
|
|
| 20 |
EGFR C797S as a Resistance Mechanism of Lazertinib in Non-small Cell Lung Cancer with EGFR T790M Mutation
Sehhoon Park, Bo Mi Ku, Hyun Ae Jung, Jong-Mu Sun, Jin Seok Ahn, Se-Hoon Lee, Keunchil Park, Myung-Ju Ahn
Cancer Res Treat.2020;52(4):1288-1290. Published online 2020 June 22
DOI: http://dx.doi.org/10.4143/crt.2020.278
|
|
